HomeNDC LookupIngredientsCromolyn Sodium › 61314-0237-10
Cromolyn Sodium 40 mg/mL Solution/ Drops, 10 mL — NDC 61314-0237-10 package photo

Cromolyn Sodium 40 mg/mL Solution/ Drops, 10 mL

by Sandoz Inc · 10 mL in 1 BOTTLE, PLASTIC (61314-237-10)
NDC 61314-0237-10
🏷️ FDA NDC (as labeled) 61314-237-10 billing pads the product segment with a zero
Rx only Generic On market Non-controlled
🗂️ Data synced Aug 13, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

🆔 Identity & classification

FDA NDC (as labeled) 61314-237-10
Product NDC 61314-237
11-digit billing NDC 61314023710
NCPDP billing unit ML — per mL (volume)
RxCUI 831109
UNII Q2WXR1I0PK
UPC 0361314237101
Application # ANDA075282
SPL Set ID b32851c3-cd97-4be4-a09c-1deab1d6966b
Established class (EPC) Mast Cell Stabilizer
Physiologic effect Decreased Histamine Release
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1999-06-29
Route OPHTHALMIC
Dosage form SOLUTION/ DROPS
Substance CROMOLYN SODIUM
GCN Seq No 044694
GCN 69069
HICL code 004526
Ingredient (HICL) Cromolyn Sodium
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6U
Therapeutic class — specific (HIC3) Eye Mast Cell Stabilizers
AHFS code 48:10.32.00
AHFS class Mast-Cell Stabilizers
FDB label name CROMOLYN 4% EYE DROPS
FDB brand name Cromolyn Sodium
Legend status F — Federal legend — prescription drug or device
Why two NDCs? The FDA registers this code as 61314-237-10 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 61314-0237-10. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Mast Cell Stabilizer class.

Pharmacologic class Mast Cell Stabilizer
Drug family (ATC) Antiallergic agents, excl. corticosteroids, Agents for dermatitis, excluding corticosteroids, Antiallergic agents, excl. corticosteroids
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerSandoz Inc
Application holderSANDOZ INC
FDA applicationANDA075282 (ANDA)
Labeler code61314
First marketedJun 1999
Product typeHuman Prescription Drug
Portfolio387 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name CROMOLYN 4% EYE DROPS Ingredient Cromolyn Sodium
📖 What it is MedlinePlus · NLM

Cromolyn ophthalmic is used to treat the symptoms of allergic conjunctivitis (a condition in which the eyes become itchy, swollen, red, and teary when they are exposed to certain substances) and keratitis (a condition that causes swelling of the cornea [tissue in the front of the eye] that causes eye redness, pain, and tearing and changes in vision) in adults and children 4 years of age and older. Cromolyn is in a class of medications called mast cell stabilizers. It works by preventing the release of substances that cause inflammation (swelling) of the eyes.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It's actually for a specific group of recurring seasonal allergic eye conditions called vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. 'Vernal' means the...
  • What exactly is this eye drop treating — is it just regular eye allergies?
  • Most people start to notice less itching, tearing, redness, and discharge within a few days of using the drops consistently. That said, for some people it can take up to six weeks...
  • How long before these drops actually start helping?
📖 Read our full Cromolyn Ophthalmic guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII F5UM2KM3W7
    Benzalkonium chloride is a chemical compound that works as a preservative and antimicrobial agent in medications. It prevents bacterial and fungal growth in liquid formulations to keep the product safe during storage and use.
  • UNII 7FLD91C86K
    Edetate disodium is a chemical compound that binds and removes certain metal ions. In medicines, it acts as a preservative and stabilizer by preventing metals like calcium from interfering with the product's shelf life and consistency.
  • UNII QTT17582CB
    A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
  • UNII 55X04QC32I
    A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

5 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMedingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.585 $5.85 / 10 ml
Medicaid paysCMS SDUD · 12 mo $2.05 $20.46 / 10 ml
Medicare drug plans payPart D · Q2 2026 $1.71 $17.12 / 10 ml
NADAC price history (per mL) — tap or hover for the price & month
Dec 2021 Jul 2022 Dec 2025 Aug 2026 $0.621 $0.513
▼ Down 6% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Cromolyn Sodium 40 mg/mLthis 61314-0237-10 Sandoz 10 ml $0.584 Availability likely
Cromolyn Sodium 40 mg/mL 50090-1202-00 A-S 10 ml FDA listed
Cromolyn Sodium 40 mg/mL 68788-8490-01 Preferred 10 ml FDA listed
Cromolyn Sodium 40 mg/mL 71205-0230-10 Proficient 10 ml FDA listed
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1999
On the market since
Jun 1999
📍
2026
Currently FDA-listed
27 years listed
🔓
·
Generic on the market
this product is a generic
This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 61314-0237-10, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
71K
Units reimbursed last 4 qtrs
735.9K
Gross reimbursed last 4 qtrs
$1.51M
Avg / prescription
$21.20
Avg / unit
$2.0462
Latest quarter Q4 2025
14KRx
Medicaid pays / mL
$2.0462
gross reimbursed
vs
NADAC / mL
$0.5845
acquisition cost
=
Spread
+$1.4617
+250% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care
58% FFS 42% MCO
Fee-for-service · 40,974 Rx Managed care · 30,052 Rx
State Medicaid map
Alaska: no data reported AK Maine: 480 units · 34.4 per 100k residents ME Washington: 3,280 units · 42.0 per 100k residents WA Idaho: 3,280 units · 167 per 100k residents ID Montana: 620 units · 54.8 per 100k residents MT North Dakota: no data reported ND Minnesota: 2,540 units · 44.3 per 100k residents MN Wisconsin: 4,100 units · 69.4 per 100k residents WI Michigan: 13,915 units · 139 per 100k residents MI New York: 227,620 units · 1,163 per 100k residents NY Vermont: 340 units · 52.6 per 100k residents VT New Hampshire: 170 units · 12.1 per 100k residents NH Oregon: 2,170 units · 51.3 per 100k residents OR Nevada: 2,880 units · 90.2 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 1,190 units · 37.1 per 100k residents IA Illinois: 12,450 units · 99.2 per 100k residents IL Indiana: 2,620 units · 38.2 per 100k residents IN Ohio: 8,160 units · 69.2 per 100k residents OH Pennsylvania: 16,566 units · 128 per 100k residents PA New Jersey: 20,690 units · 223 per 100k residents NJ Massachusetts: 15,192 units · 217 per 100k residents MA California: 149,840 units · 385 per 100k residents CA Utah: no data reported UT Colorado: 4,700 units · 80.0 per 100k residents CO Nebraska: 610 units · 30.8 per 100k residents NE Missouri: 1,760 units · 28.4 per 100k residents MO Kentucky: 3,480 units · 76.9 per 100k residents KY West Virginia: 1,840 units · 104 per 100k residents WV Virginia: 10,530 units · 121 per 100k residents VA Maryland: 9,370 units · 152 per 100k residents MD Connecticut: 14,760 units · 408 per 100k residents CT Rhode Island: 5,280 units · 482 per 100k residents RI Arizona: 20,970 units · 282 per 100k residents AZ New Mexico: 6,150 units · 291 per 100k residents NM Kansas: no data reported KS Arkansas: 590 units · 19.2 per 100k residents AR Tennessee: 1,640 units · 23.0 per 100k residents TN North Carolina: 28,685 units · 265 per 100k residents NC South Carolina: 2,100 units · 39.1 per 100k residents SC Delaware: 690 units · 66.9 per 100k residents DE Oklahoma: 2,680 units · 66.1 per 100k residents OK Louisiana: 4,780 units · 105 per 100k residents LA Mississippi: 1,060 units · 36.1 per 100k residents MS Alabama: 1,350 units · 26.4 per 100k residents AL Georgia: 29,360 units · 266 per 100k residents GA D.C.: 1,840 units · 271 per 100k residents DC Hawaii: 4,070 units · 284 per 100k residents HI Texas: 62,300 units · 204 per 100k residents TX Florida: 27,170 units · 120 per 100k residents FL
Units reimbursed · per 100k residents
12.11,163
gray = no data reported
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New York 1,163 /100k
2 Rhode Island 482 /100k
3 Connecticut 408 /100k
4 California 385 /100k
5 New Mexico 291 /100k
6 Hawaii 284 /100k
7 Arizona 282 /100k
8 D.C. 271 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Cromolyn Sodium — the program that covers self-administered drugs. 7 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Cromolyn Sodium. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$3.73M
Claims incl. refills
26.3K
Beneficiaries
18.7K
Spend / beneficiary
$199.42
Spend / claim
$142.02
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Cromolyn sodium — the ingredient across all brands.

Top reported reactions

Treatment Failure1,005
Fatigue226
Nausea197
Headache189
Diarrhoea163
Dyspnoea158
Urticaria146

Age at onset

Neonate1
Infant2
Child26
Adolescent24
Adult429
Elderly127

Reporter sex

3,585 reports
Male · 27%
Female · 73%
Unknown · 0%

Serious outcomes

Hospitalization433
Disabling69
Life-threatening62
Death48
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 1,119 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
61314-0237-10 You're viewing this 10 mL in 1 BOTTLE, PLASTIC (61314-237-10) 1999-06-29 Active

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 22 words

INDICATIONS AND USAGE Cromolyn Sodium Ophthalmic Solution USP, 4% is indicated in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.

⏱️ Dosage and Administration 113 words

DOSAGE AND ADMINISTRATION The dose is 1 or 2 drops in each eye 4 to 6 times a day at regular intervals. One drop contains approximately 1.6 mg cromolyn sodium. Patients should be advised that the effect of cromolyn sodium ophthalmic solution therapy is dependent upon its administration at regular intervals, as directed.

Symptomatic response to therapy (decreased itching, tearing, redness, and discharge) is usually evident within a few days, but longer treatment for up to six weeks is sometimes required. Once symptomatic improvement has been established, therapy should be continued for as long as needed to sustain improvement. If required, corticosteroids may be used concomitantly with Cromolyn Sodium Ophthalmic Solution USP, 4%.

Contraindications 26 words

CONTRAINDICATIONS Cromolyn Sodium Ophthalmic Solution USP, 4% is contraindicated in those patients who have shown hypersensitivity to cromolyn sodium or to any of the other ingredients.

🤒 Adverse Reactions 81 words

ADVERSE REACTIONS The most frequently reported adverse reaction attributed to the use of cromolyn sodium ophthalmic solution, on the basis of reoccurrence following readministration, is transient ocular stinging or burning upon instillation. The following adverse reactions have been reported as infrequent events. It is unclear whether they are attributable to the drug: Conjunctival injection; watery eyes; itchy eyes; dryness around the eye; puffy eyes; eye irritation; and styes.

Immediate hypersensitivity reactions have been reported rarely and include dyspnea, edema and rash.

🤰 Pregnancy 1 words

Pregnancy

🧒 Pediatric Use 17 words

Pediatric Use Safety and effectiveness in children below the age of 4 years have not been established.

🧬 Clinical Pharmacology 206 words

CLINICAL PHARMACOLOGY In vitro and in vivo animal studies have shown that cromolyn sodium inhibits the degranulation of sensitized mast cells which occurs after exposure to specific antigens. Cromolyn sodium acts by inhibiting the release of histamine and SRS-A (slow-reacting substance of anaphylaxis) from the mast cell. Another activity demonstrated in vitro is the capacity of cromolyn sodium to inhibit the degranulation of non-sensitized rat mast cells by phospholipase A and the subsequent release of chemical mediators.

Another study showed that cromolyn sodium did not inhibit the enzymatic activity of released phospholipase A on its specific substrate. Cromolyn sodium has no intrinsic vasoconstrictor, antihistaminic or anti-inflammatory activity. Cromolyn sodium is poorly absorbed.

When multiple doses of cromolyn sodium ophthalmic solution are instilled into normal rabbit eyes, less than 0.07% of the administered dose of cromolyn sodium is absorbed into the systemic circulation (presumably by way of the eye, nasal passages, buccal cavity and gastrointestinal tract). Trace amounts (less than 0.01%) of the cromolyn sodium dose penetrate into the aqueous humor and clearance from this chamber is virtually complete within 24 hours after treatment is stopped. In normal volunteers, analysis of drug excretion indicates that approximately 0.03% of cromolyn sodium is absorbed following administration to the eye.

📦 How Supplied / Storage and Handling 50 words

HOW SUPPLIED Cromolyn Sodium Ophthalmic Solution USP, 4% is supplied in a white, opaque, plastic ophthalmic dispenser in the following size: 10 mL NDC 61314-237-10 Storage: Store between 15° to 30°C (59° to 86°F). Protect from light-store in original carton. Keep tightly closed. KEEP OUT OF THE REACH OF CHILDREN.

📋 Description 69 words

DESCRIPTION Cromolyn Sodium Ophthalmic Solution USP, 4% is a clear, colorless, sterile solution intended for topical ophthalmic use. Cromolyn sodium is represented by the following structural formula: Chemical Name: Disodium 5-5'-[(2-hydroxytrimethylene)dioxy]bis[4-oxo-4H-1-benzopyran-2-carboxylate] Pharmacologic Category: Mast cell stabilizer. Each mL contains: Active: cromolyn sodium 40 mg (4%); Preservative: benzalkonium chloride 0.01%.

Inactives: edetate disodium 0.1% and purified water. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH (4.0-7.0). chemicalstructure

💬 Information for Patients 57 words

Information for the Patient Patients should be advised to follow the patient instructions listed on the Information for Patients sheet. Users of contact lenses should refrain from wearing lenses while exhibiting the signs and symptoms of vernal keratoconjunctivitis, vernal conjunctivitis, or vernal keratitis. Do not wear contact lenses during treatment with Cromolyn Sodium Ophthalmic Solution USP, 4%.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.